INTRODUCTION
According to the most common concept, the degradation of the cholesterol side chain in the biosynthesis of bile acids starts with a mitochondrial 26-hydroxylation followed by an oxidation to give a carboxylic acid (1, 2) . After further oxidation by introduction of a hydroxyl group in 24-position, propionic acid is cleaved off and the bile acid is obtained. In the biosynthesis of chenodeoxycholic acid, the most likely substrates for the 26-hydroxylase seem to be 513-cholestane-3a,7a,diol and 7a-hydroxy-4-cholesten-3-one, whereas 5#-cholestane-3ca,7a,12a-triol and 7a,12a-dihydroxy-4-cholesten-3-one are likely substrates in the biosynthesis of cholic acid (1) (2) (3) (4) (5) (6) . In a recent work (7), we showed that the liver of a patient with the rare inherited metabolic disease cerebrotendinous xanthomatosis (CTX)l was completely devoid of mito-I Abbreviations used in this paper: CTX, cerebrotendinous xanthomatosis; GC-MS, gas chromatography-mass spectrometry; HPLC, high-performance liquid chromatography.
chondrial 26-hydroxylase activity. In the liver of this patient there was a considerable accumulation of the above steroids, believed to be major substrates for the mitochondrial 26-hydroxylase (6) . 2 In addition a pathway has been described involving a microsomal 25-hydroxylation followed by a 24f3-hydroxylation (8, 9) . Further oxidation of the 24,3-,25-dihydroxylated side chain yields acetone and a bile acid. The microsomal 25-hydroxylase has a high specificity towards 5f-cholestane-3a,7a,12a-triol (3) , and consequently cholic acid is the major product of this pathway.
The relative importance of the two pathways is controversial. Patients with CTX are known to excrete considerable amounts of 5f-cholestane-3a,7a-12a , 25- tetrol and 5f3-cholestane-3a,7a,12a,24,25-pentol in bile and feces (10) . We have suggested that this excretion is due to the lack of the mitochondrial 26-hydroxylase required for normal bile acid biosynthesis.
Accumulation of 5#3-cholestane-3a,7a,12a-triol might lead to an exposure of this steroid to the otherwise less active microsomal 25-hydroxylase.
In contrast, Salen et al. have discussed the possibility that the 25-hydroxylase pathway may be the major pathway in the formation of cholic acid in human liver (8, 9) . If so, the basic metabolic defect in CTX is a reduced capacity to convert 5f3-cholestane3a,7a,12a,25-tetrol into cholic acid. The authors found a delayed conversion of labeled 5f3-cholestane3a,7a,12a,25-tetrol into cholic acid in vivo (8, 9 ) and a relatively low 243-hydroxylase activity in vitro (reduced to one-fourth) in patients with CTX as compared to control subjects (11) . Also the conversion of labeled 5fl-cholestane-3a,7a,26-triol and 7a-hydroxy-4-cholesten-3-one into cholic acid and chenodeoxycholic acid in vivo appeared to be impaired in patients with CTX (12 
RESULTS
Conversion of [4-14C] 7a-hydroxy-4-cholesten-3-one and [6,3-3H] 7a,26-dihydroxy-4-cholesten-3-one into bile acids. After administration of the above mixture to the two control subjects (L.A. and P.L.I.), 17 and 75%, respectively, of the administered 3H activity and -28 and 73%, respectively, of the administered "4C activity was recovered in the ether extract of the hydrolyzed bile sample collected. The lower recovery of bile from patient L.A. may have been due to an unfavorable position of the Lagerlof tube. The percentage of the 3H activity in cholic acid and chenodeoxycholic acid recovered in the ether extract is given in Table I . In addition to cholic acid and chenodeoxycholic acid, radioactivity was found in other fractions, the identity of which was not investigated. After further purification of the chenodeoxycholic acid fraction and crystallization of the cholic acid fraction to constant specific radioactivity, the ratio between 14C and 'H was determined. This ratio was -1.5 in the cholic acid fraction and -0.4 in the chenodeoxycholic acid fraction from both control subjects (Table I) .
After administration of the same mixture to the CTX-patient (I.J.), -73% of the administered 3H activity and -9% of the administered "C activity was recovered in the ether extract of the hydrolyzed bile sample collected. After purification and crystallization as above, the ratio between 14C and 3H was found to be -0.03 in the cholic acid fraction and -0.006 in the chenodeoxycholic acid fraction (Table I) . These findings indicate a much less efficient conversion of the non-26-hydroxylated precursor into the primary bile acids than of the 26-hydroxylated precursor.
Conversion of [4-14C] 513-cholestane-3a,7a-diol and [1,2-3H]5j-cholestane-3a,7a,26-triol into cholic acid and chenodeoxycholic acid. After administration of the above mixture to the control subject, -70% of the 3H activity and -42% of the 14C activity was recovered in the ether extract of the hydrolyzed bile sample collected. The percentage of the 3H activity in the ether extract recovered in cholic acid and chenodeoxycholic acid is given in Table I . After purification and crystallization, the ratio between 14C and 3H was found to be -0.7 in the cholic acid fraction and -0.10 in the chenodeoxycholic acid fraction (Table I ).
After administration of the same mixture to the CTX-patient (A.F.), -67% of the 3H activity and -19% of the '4C activity was found in the ether extract of the hydrolyzed bile acid sample collected. The fraction of the 3H activity in the ether extract recovered in cholic acid and chenodeoxycholic acid is given in Table I . After purification and crystallization, the ratio between '4C and 3H was found to be -0.06 in the cholic acid fraction and -0.004 in the chenodeoxycholic acid fraction (Table I) . Again, these findings indicate a much less efficient conversion of the non-26-hydroxylated precursor.
The essential results of the in vivo experiments are also summarized in Fig. 1 .
DISCUSSION
In previous in vitro studies we have presented evidence that the metabolic defect in CTX most probably is a lack of hepatic mitochondrial C27-steroid 26-hydroxylase (6, 7, 21) . If the 26-hydroxylase is important in the normal biosynthesis of bile acids and this enzyme is defective in CTX, one would expect 26-hydroxylated precursors to be rapidly converted into primary bile acids in patients with CTX as well as in control subjects. In the present in vivo study this was also found to be the case. Thus, the conversion of 3H-labeled 26-hydroxylated precursors into cholic acid + chenodeoxycholic acid was efficient in the CTX-patients as well as in the control subjects. In particular, the recovery in bile as chenodeoxycholic acid of the 3H-labeled 26-hydroxylated precursors was about the C'/I/T 0.004 formed in the control subjects is not likely to be changed with time. In the CTX-patients, however, there is probably a primary conversion of C'4-labeled 5,B-cholestane-3a,7a-diol and 7a-hydroxy-4-cholesten-3-one into the 25-hydroxylated pentols and tetrols, which are then slowly converted into cholic acid and possibly, to a small extent, also into chenodeoxycholic acid. Thus, the ratio between 14C and 3H in the primary bile acids in the CTX-patients may increase with time. In view of this, even more drastic differences between the CTX-patients and the control patients could have been obtained if the bile samples had been taken earlier after the administration, and less drastic differences could have been obtained if the samples had been taken later after the administration. Conclusions can thus be drawn from a single ratio determination only if marked differences are obtained. In the present experiments marked differences were in fact observed in the bile collected at a time interval of 14 h after the infusion. By that time all intermediates would normally be converted into bile acids and excreted in the bile (23) (24) and the marked reduction in the 14C/3H ratio observed in the CTX patients as compared with the controls, must reflect a defective conversion of the "4C-labeled, non-26-hydroxylated precursors.
Introduction of a 26-hydroxyl group in 7a-hydroxy-4-cholesten-3-one and 5#-cholestane-3a,7a-diol was found to increase the conversion into chenodeoxycholic acid in the control subjects with a factor of -2 (the "4C/3H ratio was reduced by a factor of 2). This is in accordance with the previous finding that these 26-hydroxylated steroids are efficient precursors to chenodeoxycholic acid in vivo (1, 4, 25) . In the biosynthesis of cholic acid, however, the presence of a 26-hydroxyl group reduced the biosynthesis with a factor of -50 and 75%, respectively, indicating that the 12a-hydroxyl group is introduced more easily before the 26-hydroxyl group. Both these experiments are in accord with previous concepts with respect to the major pathway in the biosynthesis of cholic acid and chenodeoxycholic acid (1, 2).
The distribution of "4C-activity from 5#3-cholestane3a,7a-diol into cholic acid in the control subject was higher than could be expected, and the corresponding distribution into chenodeoxycholic acid was lower.
According to current concepts 513-cholestane-3a,7a-diol should preferably be converted into chenodeoxycholic acid. On the other hand, individual variations may occur in the present type of in vivo experiments, and the findings obtained do not affect the general conclusions from the experiment.
In the present experiments, more marked differences were found with 7a-hydroxy-4-cholesten-3-one and 7a,26-dihydroxy-4-cholesten-3-one than with 5,3-cholestane-3a,7a-diol and 5#-cholestane-3a,7a,26-triol.
It should be pointed out that different CTX-patients with different liver pathology were studied in the two sets of experiments, and thus individual variations may occur. In any case both sets of studies give rise to the same general conclusion.
There are several pitfalls in studies in vivo with labeled precursors. Some of the difficulties can be reduced with the present experimental approach, using two different precursors (with different labels) that reach the liver simultaneously. With the technique used, the errors and inconveniences related to estimation of absolute rates of synthesis could be avoided. The present results are in accordance with the contention that the basic metabolic defect in CTX is a lack of the 26-hydroxylase. When taken together with the in vitro data (6, 7) and other in vivo data (4, 23, 26) , the present work also gives strong support for the concept that the 26-hydroxylase pathway is most important in the normal synthesis of bile acids.
